HighTower Advisors’s Zevra Therapeutics ZVRA Stock Holding History

HighTower Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.04M	Buy	+72,300	New	+$804K	﹤0.01%	2216
2019 Q4	–	Sell	-1,469	Closed	-$16K	–	2554
2019 Q3	$16K	Buy	1,469 +531	+57%	+$9.6K	﹤0.01%	2284
2019 Q2	$26K	Buy	938 +297	+46%	+$7.46K	﹤0.01%	2250
2019 Q1	$17K	Hold	641	–	–	﹤0.01%	2186
2018 Q4	$18K	Buy	+641	New	+$25.9K	﹤0.01%	2094

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HighTower Advisors's ZVRA Position: Q2 2026 in Review

HighTower Advisors opened a new position in Zevra Therapeutics (ZVRA) in Q2 2026: 72,300 shares worth $1.04M. The stake represents ﹤0.01% of the portfolio and ranks #2216 among its holdings. This is a return to the name: HighTower Advisors previously reported a position in ZVRA as recently as Q3 2019.

HighTower Advisors first reported a position in ZVRA in Q4 2018 and has held it in 5 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

HighTower Advisors held 72,300 shares of Zevra Therapeutics worth $1.04M as of Q2 2026.
Zevra Therapeutics was a new HighTower Advisors position in Q2 2026.
Zevra Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #2216 holding.
HighTower Advisors first reported a position in Zevra Therapeutics in Q4 2018 and has held it in 5 quarters since.
157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.